US FDA approves expanded use of Moderna's RSV vaccine for at-risk adults

  • The U.S. Food and Drug Administration on Thursday expanded the use of Moderna's respiratory syncytial virus vaccine to a lower group of high-risk adults aged 18 to 59 years.